MannKind Corporation (MNKD)

Market Cap	994.91M -35.5%
Revenue (ttm)	348.97M +22.2%
Net Income	5.86M -78.7%
EPS	0.02 -80.8%
Shares Out	307.07M
PE Ratio	168.91
Forward PE	49.31
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,338,568
Open	3.700
Previous Close	3.500
Day's Range	2.935 - 3.720
52-Week Range	2.935 - 6.510
Beta	0.76
Analysts	Strong Buy
Price Target	10.08 (+211.11%)
Earnings Date	Feb 26, 2026

About MNKD

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 28, 2004
• Employees: 407
• Stock Exchange: NASDAQ
• Ticker Symbol: MNKD
• Website: https://www.mannkindcorp.com

Financial Performance

In 2025, MannKind's revenue was $348.97 million, an increase of 22.23% compared to the previous year's $285.50 million. Earnings were $5.86 million, a decrease of -78.75%.

Analyst Summary

According to 6 analysts, the average rating for MNKD stock is "Strong Buy." The 12-month stock price target is $10.08, which is an increase of 211.11% from the latest price.

Price Target

$10.08

(211.11% upside)

Analyst Consensus: Strong Buy